Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Roy, Sanchita ^a   Levi, Edi ^a   Majumdar, Adhip Pn ^a   Sarkar, Fazlul H ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDF; Colon cancer; Methylation; MiR 34c; MiR34a

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CURCUMIN; DIFLUORINATED CURCUMIN; FORMALDEHYDE; MICRORNA; MICRORNA 34A; MICRORNA 34C; NOTCH1 RECEPTOR; PARAFFIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CHEMOSENSITIVITY; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION PROCESSING; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE SECTION;

CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CURCUMIN; DNA METHYLATION; DOWN-REGULATION; FLUOROCARBONS; HCT116 CELLS; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84866280242     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-58     Document Type: Article

References (36)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. The clinical correlation of an autopsy study of recurrent colorectal cancer. Welch JP, Donaldson GA, Ann Surg 1979 189 496 502 443905
3. Tumour stem cells and drug resistance. Dean M, Fojo T, Bates S, Nat Rev Cancer 2005 5 275 284 10.1038/nrc1590 15803154
4. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438
5. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Lewis BP, Burge CB, Bartel DP, Cell 2005 120 15 20 10.1016/j.cell.2004.12.035 15652477
6. MicroRNAs in Cancer. Garzon R, Calin GA, Croce CM, Annu Rev Med 2009 60 167 179 10.1146/annurev.med.59.053006.104707 19630570
7. MicroRNA regulation of cancer stem cells. Liu C, Tang DG, Cancer Res 2011 71 5950 5954 10.1158/0008-5472.CAN-11-1035 21917736
8. Colon cancer stem cells: promise of targeted therapy. Todaro M, Francipane MG, Medema JP, Stassi G, Gastroenterology 2010 138 2151 2162 10.1053/j.gastro.2009.12.063 20420952
9. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. Nat Med 2011 17 211 215 10.1038/nm.2284 21240262
10. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H, Proc Natl Acad Sci U S A 2007 104 15472 15477 10.1073/pnas.0707351104 17875987
11. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T, Cancer Lett 2011 300 197 204 10.1016/j.canlet.2010.10.006 21067862
12. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY, Cancer Res 2007 67 8433 8438 10.1158/0008-5472.CAN-07-1585 17823410
13. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Mol Cell 2007 26 745 752 10.1016/j.molcel.2007.05.010 17540599
14. MiR-34, SIRT1 and p53: the feedback loop. Yamakuchi M, Lowenstein CJ, Cell Cycle 2009 8 712 715 10.4161/cc.8.5.7753 19221490
15. miR-34a repression of SIRT1 regulates apoptosis. Yamakuchi M, Ferlito M, Lowenstein CJ, Proc Natl Acad Sci U S A 2008 105 13421 13426 10.1073/pnas.0801613105 18755897
16. MicroRNAs impair MET-mediated invasive growth. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al. Cancer Res 2008 68 10128 10136 10.1158/0008-5472.CAN-08-2148 19074879
17. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Mol Cell 2007 26 731 743 10.1016/j.molcel.2007.05.017 17540598
18. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, et al. Pharm Res 2009 26 1874 1880 10.1007/s11095-009-9900-8 19421843
19. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, et al. Pharm Res 2009 26 2438 2445 10.1007/s11095-009-9955-6 19714451
20. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al. Cancer Res 2010 70 3606 3617 10.1158/0008-5472.CAN-09-4598 20388782
21. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, et al. Cancer Lett 2012 319 173 181 10.1016/j.canlet.2012.01.013 22261338
22. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al. PLoS One 2011 6 17850 10.1371/journal.pone.0017850 21408027
23. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, et al. Cancer Res 2012 72 335 345 10.1158/0008-5472. CAN-11-2182 22108826
24. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, et al. Pharm Res 2011 28 827 838 10.1007/s11095-010- 0336-y 21161336
25. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP, Mol Cancer 2010 9 212 10.1186/1476-4598-9-212 20691072
26. Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP, Transl Oncol 2009 2 321 328 19956394
27. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, et al. Carcinogenesis 2012 33 68 76 10.1093/carcin/bgr246 22072622
28. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Cell Cycle 2008 7 2591 2600 10.4161/cc.7.16.6533 18719384
29. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, et al. Am J Transl Res 2012 4 14 23 22347519
30. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. Nature 2005 435 834 838 10.1038/nature03702 15944708
31. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al. Virchows Arch 2011 458 313 322 10.1007/s00428-010-1030-5 21225432
32. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Cowan LA, Talwar S, Yang AS, Epigenomics 2010 2 71 86 10.2217/epi.09.44 22122748
33. The miR-34 family in cancer and apoptosis. Hermeking H, Cell Death Differ 2010 17 193 199 10.1038/cdd.2009.56 19461653
34. Molecular genetics of colorectal cancer. Fearon ER, Annu Rev Pathol 2011 6 479 507 10.1146/annurev-pathol-011110-130235 21090969
35. MicroRNA and cancer: Current status and prospective. Wu W, Sun M, Zou GM, Chen J, Int J Cancer 2007 120 953 960 17163415
36. Cancer stem cells. Jordan CT, Guzman ML, Noble M, N Engl J Med 2006 355 1253 1261 10.1056/NEJMra061808 16990388